Johnson & Johnson (NYSE:JNJ) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP increased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,356,572 shares of the company’s stock after acquiring an additional 431,205 shares during the quarter. Johnson & Johnson makes up 0.6% of Wellington Management Group LLP’s portfolio, making the stock its 26th biggest position. Wellington Management Group LLP’s holdings in Johnson & Johnson were worth $3,522,447,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Partners in Financial Planning bought a new position in Johnson & Johnson during the 4th quarter valued at $407,000. Everstar Asset Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $428,000. Delos Wealth Advisors LLC grew its stake in Johnson & Johnson by 3.3% in the fourth quarter. Delos Wealth Advisors LLC now owns 2,530 shares of the company’s stock worth $366,000 after purchasing an additional 80 shares in the last quarter. Prevail Innovative Wealth Advisors LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at about $209,000. Finally, United Bank raised its stake in Johnson & Johnson by 16.2% during the fourth quarter. United Bank now owns 4,403 shares of the company’s stock valued at $637,000 after buying an additional 615 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on JNJ. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Up 0.3 %

JNJ opened at $163.63 on Monday. The stock’s fifty day moving average is $158.68 and its 200-day moving average is $156.07. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a market capitalization of $394.32 billion, a PE ratio of 24.61, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.29 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.